TOKYO, Japan & MUNICH, Germany I April 08, 2025 I DATROWAY® (datopotamab deruxtecan) has been approved in the European Union (EU) for the treatment of ...
Merus leads biotech with its innovative antibody platforms, strong financials, and promising petosemtamab targeting cancer.
In April 2025, Amgen announced a study is to evaluate the safety, tolerability, and to determine the maximum tolerated dose ...
AcumenX, a premier C-Suite advisory firm, today announced the addition of Brian Keane and Lucia Wind as Senior Advisors. With decades of expertise in investment banking, governance, risk management, ...
In a small study, lactotransferrin (LTF) was identified as a potentially important biomarker in extensive-stage small cell ...
Pembrolizumab plus concurrent chemoradiotherapy shows ongoing antitumor activity after about 5 years of follow-up in patients ...
Enriqueta Felip, MD, PhD, discusses the phase 3 3475A-D77 study of subcutaneous pembrolizumab plus chemotherapy in metastatic non–small cell lung cancer.
Combining savolitinib with osimertinib can reverse osimertinib resistance in patients with advanced, EGFR-mutant NSCLC, data suggest.
The only update for patients with stage IV NSCLC without driver alterations is that patients who have HER2-overexpressing (IHC 3+) disease and good performance status can receive trastuzumab ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback